产品
编 号:F040833
分子式:C33H29F2N5O4S
分子量:629.68
产品类型
结构图
CAS No: 1123837-84-2
联系客服
产品详情
生物活性:
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
体内研究:
Sitravatinib (20 mg/kg;口服;每天一次,持续 6 天) 在携带 CT1B-A5 细胞模型的 C57BL/6 小鼠中显着抑制肿瘤进展并诱导肿瘤消退。Animal Model:6-week-old C57BL/6 mice (bearing CT1B-A5 cells)
Dosage:20 mg/kg
Administration:Oral administration; once per day for 6 days
Result:Significantly inhibited tumor progression and induced tumor regression.
体外研究:
Sitravatinib (0.01 nM-10 μM;14 天) 在 KLN205 和 E0771 细胞系中以剂量依赖性方式减少集落形成。 Sitravatinib (0.001-10 μM;5 天) 在 KLN205、E0771 和 CT1B-A5 细胞系中抑制肿瘤细胞活力,IC50 约为 1 μM。